Flash Finance

Suven Life Sciences LimitedSUVENCorporate

Healthcare Research, Analytics & Technology Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹303.55
MCap ₹8,577 Cr
Suven Life Sciences Limited — Stock analysis & AI research Suven Life Sciences Limited — Multibagger AI analysis Suven Life Sciences Limited — Seasonality — best & worst months Suven Life Sciences Limited — Technical indicators & charts Suven Life Sciences Limited — Technical setup — score, trend, support & resistance Suven Life Sciences Limited — Live exchange announcements
🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹4 Cr
Sales · Jun 2026
+91.0% YoY
₹-21 Cr
Operating Profit · Jun 2026
-50.1% YoY
-589.3%
OPM % · Jun 2026
+21.4% YoY
₹-16 Cr
Net Profit · Jun 2026
-9.1% YoY
₹-0.61
EPS · Jun 2026
+10.3% YoY

📝 Suven Life Sciences Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Suven Life Sciences Limited reported revenue of ₹4 crore for the quarter ended June 2026 (Q1 FY27), up 91.0% from ₹2 crore in the same quarter last year, and up 134.6% sequentially over the March 2026 quarter.

The company reported a net loss of ₹16 crore, against a net loss of ₹15 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.61.

Operating profit stood at ₹-21 crore — an operating margin (OPM) of -589.3%, compared with -749.9% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Suven Life Sciences Limited posted revenue of ₹7 crore, a growth of 1.0% over FY25, with a net loss of ₹55 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹9 crore with a net loss of ₹56 crore.

Valuation snapshot

At the current price of ₹303.55, SUVEN has a market capitalisation of ₹8,577 crore.

Within the Healthcare Research, Analytics & Technology industry, it is the 2nd-largest of the 10 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 65.47%, foreign institutional investors (FIIs) 0.46%, domestic institutional investors (DIIs) 2.17%, public shareholders 31.90% of Suven Life Sciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹8,577 Cr
Current Price ?
₹303.6
P/E ?
N/A
Industry P/E ?
35.60
P/B ?
5.71
P/S ?
973.15
P/FCF ?
-114.36
Enterprise Value ?
₹8,594 Cr
EV/EBITDA ?
-122.75
PEG ?
N/A
Earnings Yield ?
-0.9%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹9 Cr
OPM ?
-794.4%
Profit after tax (TTM) ?
₹-56 Cr
EPS (TTM) ?
₹-1.99
ROCE ?
-5.0%
ROE ?
-3.7%
ROA ?
-3.7%
Growth
Sales — latest qtr ?
₹4 Cr
PAT — latest qtr ?
₹-16 Cr
YoY qtr sales growth ?
91.0%
YoY qtr profit growth ?
-9.1%
Sales growth (3y) ?
-19%
Sales growth (5y) ?
-12%
Profit growth (3y) ?
-67%
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹17 Cr
Debt to Equity ?
0.01
Interest Coverage ?
-434.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
65.47%
Change in promoter holding ?
-4.79%
Pledged percentage ?
N/A
Market
Return 3 months ?
-6.9%
Return 6 months ?
54.8%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 34322132121324 +91.0% +134.6%
Operating Profit -6-7-8-9-7-10-14-13-15-14-18-15-16-21 -50.1% -29.7%
Other Income 66564442114378 +1177.4% +11.0%
Interest 00000000000000 — +201.7%
Depreciation 22222112111122 +57.5% +36.2%
Profit Before Tax -2-33-5-4-8-11-13-15-15-15-13-11-16 -9.1% -44.3%
Net Profit -2-33-5-3-8-11-13-15-15-15-13-11-16 -9.1% -44.3%
EPS -0.05-0.130.13-0.22-0.14-0.35-0.51-0.61-0.69-0.68-0.70-0.60-0.50-0.61 +10.3% -22.0%
OPM % -234.9% -178.9% -263.9% -375.3% -288.0% -1002.7% -530.0% -650.0% -1016.6% -749.9% -1948.0% -530.2% -1066.0% -589.3% +21.4% +44.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹7 Cr ₹7 Cr ₹9 Cr +1.0%
Operating Profit ₹-52 Cr ₹-63 Cr ₹-70 Cr -22.0%
OPM % -732.87% -885.52% -794.37% -20.8%
NPM % -664.33% -771.12% -637.67% -16.1%
Other Income ₹11 Cr ₹14 Cr ₹21 Cr +24.7%
Depreciation ₹6 Cr ₹6 Cr ₹6 Cr -10.7%
Interest ₹0 Cr ₹0 Cr ₹1 Cr +307.8%
EBIT ₹-58 Cr ₹-69 Cr ₹-76 Cr -18.5%
PBT ₹-47 Cr ₹-55 Cr ₹-56 Cr -17.2%
Tax — — — —
Net Profit ₹-47 Cr ₹-55 Cr ₹-56 Cr -17.2%
EPS ₹-2.16 ₹-2.48 ₹-2.41 -14.8%
Material Cost — — — —
Employee Cost ₹16 Cr ₹24 Cr ₹25 Cr +51.3%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 22222226 +18.2%
Reserves 8328247781,477 +89.8%
Borrowings 21017 —
Other Liabilities 55911 +22.2%
Total Liabilities 8608518091,531 +89.2%
Fixed Assets 37286073 +21.7%
CWIP 0004 —
Investments 5286537141,094 +53.2%
Other Assets 29517035361 +931.4%
Total Assets 8608518091,531 +89.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -23-21-47-70 -48.9%
Cash from Investing Activity -349-144-686 -1659.1%
Cash from Financing Activity 396-1-1757 +75800.0%
Net Cash Flow 24-22-42 +150.0%
Free Cash Flow -26-18-85-75 +11.8%
CFO/OP 79%87%93%109% +17.2%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 22407378 +6.8%
Cash Conversion Cycle 22407378 +6.8%
Working Capital Days 4433754279,419 +2105.9%
ROCE % -4%-2%-6%-5% +16.7%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jul 2026Sep 2026 % Chg
Promoters 70.26%67.36%67.36%70.15%65.47%65.47% +0.0%
FIIs 0.58%1.17%1.07%0.91%0.48%0.46% -4.2%
DIIs 0.03%3.39%3.39%4.62%2.73%2.17% -20.5%
Public 29.12%28.07%28.18%24.32%31.32%31.90% +1.9%
No. of Shareholders 66,15964,92164,38163,91566,64767,431 +1.2%

⚖️ Peer comparison

Industry: Healthcare Research, Analytics & Technology · 10 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 INDGN Indegene ₹597.05 14,377 35.8 3,812 401 16.7% 10.5% 23.6% -1.5% 39.7% -0.2%
2 SUVEN Suven Life ₹286.25 8,088 — 9 -353 -3955.0% -3815.2% 6.9% -71.9% 114.3% -148.5%
3 VIMTALABS Vimta Labs ₹637.20 2,847 35.7 419 80 34.4% 19.1% 18.0% 19.5% 11.3% 10.7%
4 FABTECH Fabtech Technologies ₹145.66 647 44.8 364 14 2.4% 4.0% — — 10.3% 168.7%
5 526853 Bilcare Ltd-$ ₹61.25 215 — 773 -6 9.1% -0.8% -6.9% 36.7% 21.2% 253.4%
6 TAKE Take Solutions ₹12.69 186 14.6 85 13 -2.0% 15.2% — -71.0% — 216.8%
7 536565 Novelix Pharmaceuticals ₹19.88 181 13.2 147 4 3.1% 2.5% 330.7% 2218.2% 65.2% 971.7%
8 538837 Jeevan Scientific ₹50.96 178 22.6 71 5 20.5% 7.2% 31.4% 1371.4% 107.7% 127.0%
9 543309 Adeshwar Meditex ₹27.50 24 31.2 56 1 4.9% 2.2% — — -30.4% -60.4%
10 540729 Vanta Bioscience ₹51.45 15 333.1 2 0 55.8% 6.1% — — 357.6% 240.9%
❓ Frequently asked questions
What was Suven Life Sciences Limited's revenue in Q1 FY27?
Suven Life Sciences Limited reported revenue of ₹4 crore for the quarter ended June 2026 (Q1 FY27), up 91.0% from ₹2 crore in the same quarter last year, and up 134.6% sequentially over the March 2026 quarter.
What was Suven Life Sciences Limited's net profit in Q1 FY27?
The company reported a net loss of ₹16 crore, against a net loss of ₹15 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.61.
What is SUVEN's market capitalisation and P/E ratio?
At the current price of ₹303.55, SUVEN has a market capitalisation of ₹8,577 crore.
Who owns Suven Life Sciences Limited? (shareholding pattern)
As of Sep 2026, promoters held 65.47%, foreign institutional investors (FIIs) 0.46%, domestic institutional investors (DIIs) 2.17%, public shareholders 31.90% of Suven Life Sciences Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI